A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical And Translational Study

PURPOSE: This phase I/II study sought to determine the safety and maximum-tolerated dose (MTD) of a novel schedule of belinostat, a histone deacetylase inhibitor administered prior to and in combination with cisplatin (P), doxorubicin (A) and cyclophosphamide (C) in thymic epithelial tumors (TET). A...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Thomas, Anish, Rajan, Arun, Szabo, Eva, Tomita, Yusuke, Carter, Corey A., Scepura, Barbara, Lopez-Chavez, Ariel, Lee, Min-Jung, Redon, Christophe E., Frosch, Ari, Peer, Cody J., Chen, Yuanbin, Piekarz, Richard, Steinberg, Seth M., Trepel, Jane B., Figg, William D., Schrump, David S., Giaccone, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4216756/
https://ncbi.nlm.nih.gov/pubmed/25189481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0968
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares